#1 Clinical Trials Search in Europe

Allogeneic Bone Marrow-Derived Mesenchymal Adult Stromal Cells, Ex-Vivo Expanded

Allogeneic Bone Marrow-Derived Mesenchymal Adult Stromal Cells, Ex-Vivo Expanded, are at the forefront of innovative medical treatments. These cells, often referred to as mesenchymal stem cells (MSCs), are being studied in clinical trials for various conditions, including lung transplant rejection, intestinal strictures in Crohn’s disease, and refractory Crohn’s disease lesions. This article explores the potential of these cells in treating complex medical conditions and their safety and efficacy in ongoing clinical trials.

Table of Contents

What are Mesenchymal Stromal Cells (MSCs)?

Mesenchymal stromal cells (MSCs) are a type of adult stem cell that can be found in various tissues, including bone marrow. These cells have unique properties that make them valuable for medical treatments[1]. MSCs can:

  • Transform into different types of cells
  • Help reduce inflammation
  • Support tissue repair and regeneration
In the context of the treatments being studied, we’re specifically looking at allogeneic bone marrow-derived mesenchymal adult stromal cells. Let’s break down what this means:
  • Allogeneic: The cells come from a donor, not the patient themselves
  • Bone marrow-derived: They are extracted from bone marrow
  • Adult: These are mature cells, not embryonic stem cells
  • Stromal cells: They are support cells found in connective tissue

How are these cells obtained and prepared?

The process of obtaining and preparing these cells for treatment involves several steps[1]:

  1. Extraction: The cells are taken from a donor’s bone marrow
  2. Isolation: MSCs are separated from other types of cells in the bone marrow
  3. Expansion: The isolated MSCs are grown and multiplied in a laboratory
  4. Preparation: The expanded cells are formulated into a suspension for injection
This carefully controlled process ensures that a sufficient number of high-quality cells are available for treatment.

What conditions are being treated with MSCs?

Research is ongoing to explore the potential of MSCs in treating various conditions. Current clinical trials are focusing on[1][2][3]:

  • Chronic lung transplant rejection: Also known as bronchiolitis obliterans syndrome (BOS), this is a serious complication after lung transplantation
  • Crohn’s disease: A type of inflammatory bowel disease that can cause various complications, including:
    • Intestinal strictures (narrowing of the intestine)
    • Deep ulcers in the intestine
    • Perianal fistulas (abnormal connections between the intestine and the skin near the anus)
These conditions are often difficult to treat with conventional therapies, which is why researchers are exploring the potential of MSCs as a new treatment option.

How are MSCs administered?

The method of administering MSCs depends on the condition being treated[1][2][3]:

  • For lung transplant rejection: Endotracheopulmonary use, which means the cells are delivered directly into the airways of the lungs
  • For Crohn’s disease: Local injection into the affected areas, such as:
    • Directly into intestinal strictures during an endoscopy procedure
    • Into deep ulcers in the intestine
    • Around perianal fistulas
These targeted approaches aim to deliver the cells directly to the areas where they are needed most.

Safety and Efficacy

The primary focus of current clinical trials is to assess both the safety and effectiveness of MSC treatments[1][2][3]. Researchers are carefully monitoring for:

  • Adverse events, both immediate and long-term
  • Improvements in disease symptoms and overall patient health
  • Changes in lung function (for transplant patients)
  • Healing of intestinal lesions and fistulas (for Crohn’s disease patients)
It’s important to note that while early results are promising, these treatments are still experimental and require further study before they can be widely used.

Ongoing Research

Several clinical trials are currently underway to better understand the potential of MSCs[1][2][3]. These studies aim to:

  • Determine the optimal dose and frequency of MSC treatments
  • Identify which patients are most likely to benefit from MSC therapy
  • Understand the long-term effects of MSC treatment
  • Explore the mechanisms by which MSCs promote healing and reduce inflammation
The results of these studies will help guide future use of MSCs in treating various conditions and potentially open up new avenues for regenerative medicine.

Aspect Details
Treatment Allogeneic Bone Marrow-Derived Mesenchymal Adult Stromal Cells, Ex-Vivo Expanded
Conditions Studied Lung transplant rejection, Intestinal strictures in Crohn’s disease, Refractory Crohn’s disease lesions
Administration Methods Endotracheopulmonary use, Local injection
Primary Objectives Assess safety and efficacy in treating targeted conditions
Key Endpoints Adverse events, Healing of lesions, Improvement in disease symptoms and quality of life
Patient Populations Adults with specific diagnoses related to each condition
Trial Phases Phase I/II integrated trials

FAQ

  • What are Allogeneic Bone Marrow-Derived Mesenchymal Adult Stromal Cells? These are a type of stem cell derived from bone marrow of donors (allogeneic means from a different person). They are grown and expanded in a laboratory before being used in treatments. These cells have the potential to promote healing and reduce inflammation in various tissues.
  • What conditions are being studied using these stem cells? Current clinical trials are investigating their use in lung transplant rejection, intestinal strictures in Crohn's disease, and refractory Crohn's disease lesions. These conditions are often difficult to treat with conventional methods.
  • How are these stem cells administered to patients? The administration method varies depending on the condition being treated. For lung transplant patients, they are given through endotracheopulmonary use (into the airways). In Crohn's disease trials, they are injected locally into the affected areas of the intestine or around fistulas.
  • What are the main objectives of these clinical trials? The primary objectives are to assess the safety of the treatment and its effectiveness in improving the targeted conditions. Researchers are looking at factors such as adverse events, healing of lesions, and improvements in disease symptoms and quality of life.
  • Are there any known risks or side effects? While the trials are ongoing to determine safety, potential risks being monitored include adverse reactions like infections, allergic responses, or unexpected tissue changes. The trials have strict safety monitoring protocols in place to protect participants.

Ongoing Clinical Trials on Allogeneic Bone Marrow-Derived Mesenchymal Adult Stromal Cells, Ex-Vivo Expanded

  • Study on the Safety and Effectiveness of Mesenchymal Stem Cells for Treating Intestinal Strictures in Crohn’s Disease Patients

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on the Safety of Allogeneic Mesenchymal Stromal Cells for Patients with Chronic Lung Transplant Rejection

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Local Injection of Mesenchymal Stem Cells for Patients with Refractory Crohn’s Disease Lesions

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Allogeneic: Cells or tissues that are obtained from a different individual of the same species, as opposed to from the patient themselves.
  • Mesenchymal Stromal Cells (MSCs): A type of adult stem cell that can differentiate into various cell types and has potential anti-inflammatory and tissue-repairing properties.
  • Ex-Vivo Expanded: Cells that have been grown and multiplied outside the body in a laboratory setting before being used for treatment.
  • Endotracheopulmonary Use: Administration of a treatment directly into the airways and lungs.
  • Bronchiolitis Obliterans Syndrome (BOS): A form of chronic lung transplant rejection characterized by inflammation and scarring of the small airways.
  • Crohn's Disease: A type of inflammatory bowel disease that can affect any part of the gastrointestinal tract, causing inflammation, ulcers, and other complications.
  • Intestinal Stricture: A narrowing of the intestine that can obstruct the passage of food and waste.
  • Perianal Fistula: An abnormal connection between the anal canal and the skin around the anus, often occurring as a complication of Crohn's disease.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function often used to assess the severity of lung diseases.
  • CDAI: Crohn's Disease Activity Index, a tool used to quantify the symptoms of Crohn's disease and assess disease severity.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-of-allogeneic-mesenchymal-stromal-cells-for-patients-with-chronic-lung-transplant-rejection/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mesenchymal-stem-cells-for-treating-intestinal-strictures-in-crohns-disease-patients/
  3. http://clinicaltrials.eu/trial/study-on-local-injection-of-mesenchymal-stem-cells-for-patients-with-refractory-crohns-disease-lesions/